Genmab A/S

(PINK:GNMSF)

Latest On Genmab A/S (GNMSF):

Date/Time Type Description Signal Details
2023-05-10 23:19 ESTNewsGenmab A/S (GMAB) Q1 2023 Earnings Call TranscriptN/A
2023-04-17 15:43 ESTNewsArgenx, Genmab in pact to study antibody therapies for immunology and oncologyN/A
2023-02-23 09:01 ESTNewsGenmab A/S GAAP EPS of DKK83.65, revenue of DKK14.6B; initiates FY23 outlookN/A
2023-02-22 20:27 ESTNewsGenmab A/S (GMAB) Q4 2022 Earnings Call TranscriptN/A
2023-02-06 12:00 ESTNewsAbbVie pins hopes on newer drugs and deals to face Humira knockoffs – WSJN/A
2022-11-16 04:42 ESTNewsGenmab A/S 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-09 16:34 ESTNewsGenmab A/S (GMAB) Q3 2022 Earnings Call TranscriptN/A
2022-08-11 03:03 ESTNewsGenmab A/S (GMAB) CEO Jan van de Winkel on Q2 2022 Results - Earnings Call TranscriptN/A
2022-05-12 08:11 ESTNewsGenmab A/S (GMAB) CEO Jan van de Winkel on Q1 2022 Results - Earning Call TranscriptN/A
2022-05-12 08:11 ESTNewsGenmab A/S 2022 Q1 - Results - Earnings Call PresentationN/A
2022-02-17 07:08 ESTNewsGenmab A/S (GMAB) CEO Jan van de Winkel on Q4 2021 Results - Earning Calls TranscriptN/A
2022-02-17 07:08 ESTNewsGenmab A/S 2021 Q4 - Results - Earnings Call PresentationN/A
2021-11-10 20:38 ESTNewsGenmab A/S 2021 Q3 - Results - Earnings Call PresentationN/A
2021-11-10 20:38 ESTNewsGenmab A/S (GMAB) CEO Jan van de Winkel on Q3 2021 Results - Earnings Call TranscriptN/A
2021-08-18 01:05 ESTNewsGenmab: Monoclonal Antibody Experts, Low Risk Business ModelN/A
2021-08-12 08:12 ESTNewsGenmab A/S 2021 Q2 - Results - Earnings Call PresentationN/A
2021-08-12 08:12 ESTNewsGenmab A/S (GMAB) CEO Jan van de Winkel on Q2 2021 Results - Earnings Call TranscriptN/A
2021-05-06 03:31 ESTNewsGenmab A/S (GMAB) CEO Jan van de Winkel on Q1 2021 Results - Earnings Call TranscriptN/A
2021-03-18 23:29 ESTAnalyst RatingThe Analyst Target Price has increased from $400.12 to $402.86.Buy
2021-03-17 22:34 ESTAnalyst RatingThe Analyst Target Price has decreased from $401.77 to $400.12.Neutral
2021-03-16 22:52 ESTAnalyst RatingThe Analyst Target Price has decreased from $402.81 to $401.77.Neutral
2021-03-13 05:05 ESTAnalyst RatingThe Analyst Target Price has increased from $400.87 to $402.81.Buy
2021-03-12 13:04 ESTAnalyst RatingThe Analyst Target Price has increased from $0 to $400.87.Buy
2021-02-27 05:34 ESTNewsGenmab A/S 2020 Q4 - Results - Earnings Call PresentationN/A
2021-02-25 16:01 ESTEarnings EstimateAn EPS average of $0.67 is estimated for the quarter ending on March 31, 2021.Sell
2021-02-25 16:01 ESTEarnings EstimateAn EPS average of $0.65 is estimated for the quarter ending on June 30, 2021.Sell
2021-02-25 16:01 ESTEarnings EstimateAn EPS average of $8.81 is estimated for the 2022 year.Buy
2021-02-25 05:44 ESTFinancialsCompany financials have been released.Neutral
2021-02-24 00:41 ESTNewsGenmab A/S (GMAB) CEO Jan van de Winkel on Q4 2020 Results - Earnings Call TranscriptN/A
2020-11-26 22:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 01:16 ESTNewsGenmab A/S 2020 Q3 - Results - Earnings Call PresentationN/A
2020-11-08 01:48 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 18:11 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 05:13 ESTFinancialsCompany financials have been released.Neutral
2020-11-05 21:30 ESTNewsGenmab A/S (GMAB) CEO Jan van de Winkel on Q3 2020 Results - Earnings Call TranscriptN/A
2020-09-26 15:03 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 07:10 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 11:04 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 07:42 ESTNewsGenmab A/S 2020 Q2 - Results - Earnings Call PresentationN/A
2020-08-14 02:22 ESTFinancialsCompany financials have been released.Neutral
2020-08-13 05:48 ESTNewsGenmab A/S (GMAB) CEO Jan van de Winkel on Q2 2020 Results - Earnings Call TranscriptN/A
2020-08-06 14:40 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 10:25 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 18:49 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 06:48 ESTFinancialsCompany financials have been released.Neutral
2020-07-29 22:59 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 14:41 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 19:28 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 10:53 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 18:38 ESTFinancialsCompany financials have been released.Neutral

About Genmab A/S (GNMSF):

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and BioNTech, Janssen, Novo Nordisk A/S, and BliNK Biomedical SAS. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

See Advanced Chart

General

  • Name Genmab A/S
  • Symbol GNMSF
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 781
  • Fiscal Year EndDecember
  • Web URLhttp://www.genmab.com
View More

Valuation

  • Trailing PE 92.98
  • Forward PE 80.65
  • Price/Sales (Trailing 12 Mt.) 13.8
  • Price/Book (Most Recent Quarter) 7.25
  • Enterprise Value Revenue 1.89
  • Enterprise Value EBITDA 3.1
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate $4.27
  • Next Year EPS Estimate $7.73
  • Profit Margin 47%
  • Return on Assets 22%
  • Return on Equity 29%
  • Earnings Per Share $3.59
  • Revenue Per Share $0
  • Gross Profit 10.11 billion
  • Quarterly Earnings Growth -31%
View More

Highlights

  • Market Capitalization 21.27 billion
  • PEG Ratio 8.94
  • Analyst Target Price $402.86
  • Book Value Per Share $18.00
View More

Share Statistics

  • Shares Outstanding 65.44 million
  • Shares Float 64.68 million
  • % Held by Insiders 464%
  • % Held by Institutions 46.88%
View More

Technicals

  • Beta 0.54
  • 52 Week High $456.83
  • 52 Week Low $173.79
  • 50 Day Moving Average 369.84
  • 200 Day Moving Average 378.12
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

ESG Rating

  • Rating Date 2019-01-01
  • ESG Score 28.8
  • Environment Score 1.63
  • Social Score 20.4
  • Governance Score 7.27
  • Controversy Level 0
View More

Genmab A/S (GNMSF) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Genmab A/S (GNMSF) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31$2.04 billion$1.41$1.299.3%
2020-09-302020-12-31$N/A$1.44
2020-06-302020-09-30$5.45 billion$1.27
2020-03-312020-06-30$N/A$7.74$0.00
2019-12-312020-03-31$444.43 million$0.60$24.80-97.56%
2019-09-302019-12-31$151.81 million$3.36$3.76-10.7%
2019-06-302019-09-30$117.02 million$1.21$1.58-23.49%
2019-03-312019-06-30$88.77 million$0.21$1.41-85.41%
2018-12-312019-03-31$189.8 million$0.18$8.58-97.95%
2018-09-302018-12-31$92.95 million$2.06$3.60-42.75%
2018-06-302018-09-30$79.61 million$0.45$2.46-81.71%
2018-03-312018-06-30$112.47 million$0.66$5.60-88.22%
2017-12-312018-03-31$164.13 million$0.53$8.04-93.42%
2017-09-302017-12-31$50.99 million$2.03$1.982.77%
2017-06-302017-09-30$118.83 million-$0.01$7.37-100.19%
2017-03-312017-06-30$250.78 million$0.76
2016-12-312017-03-31$927.46 million$0.04$6.81-99.45%
2016-09-302016-12-31$1.93$0.77150%
2016-06-302016-09-30$0.46$1.59-70.96%
2016-03-312016-06-30$0.41-$0.36212.78%
2015-12-312016-03-31-$0.03$5.96-100.49%
2015-09-302015-12-31$0.95$0.97-1.74%
2015-06-302015-09-30$0.34$2.05-83.22%
2015-03-312015-06-30$0.04$3.95-98.98%
2014-12-312015-03-31$0.52$0.62-15.56%
2014-09-302014-12-31$0.19$1.35-85.65%
2014-06-302014-09-30$0.47$0.3247.28%
2014-03-312014-06-30-$0.08-$0.06-40.83%
2013-12-312014-03-31$0.32$0.1791.06%
2013-09-302013-12-31$0.21
2013-06-302013-09-30$0.02
2013-03-312013-06-30-$0.09
2012-12-312013-03-31$0.10
2012-09-302012-12-31-$0.06
2012-06-302012-09-30-$0.17
2012-03-312012-06-30$0.03
2011-12-312012-03-31-$0.25
2011-09-302011-12-31-$0.13
2011-06-302011-09-30-$0.03
2011-03-312011-06-30-$0.31
2010-12-312011-03-31-$0.43
2010-09-302010-12-31-$0.31
2010-06-302010-06-30-$0.34
2010-03-312010-03-31-$0.54
2009-12-312009-12-31-$1.57
2009-09-302009-09-30-$0.38
2009-06-302009-06-30-$0.47
2009-03-312009-03-31-$0.78
2008-12-312008-12-31-$1.74
2008-09-302008-09-30-$0.16
2008-06-302008-06-30-$1.32
2008-03-312008-03-31-$0.95
2007-12-312007-12-31-$0.54
2007-09-302007-09-30-$0.72
2007-06-302007-06-30-$0.04
2007-03-312007-03-31-$0.32

Genmab A/S (GNMSF) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Genmab A/S (GNMSF) Chart:

Genmab A/S (GNMSF) News:

Below you will find a list of latest news for Genmab A/S (GNMSF) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Genmab A/S (GNMSF) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Genmab A/S (GNMSF) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link